## PRESCRIPTION AND SERVICE REQUEST FORM

**AUSTEDO**® (deutetrabenazine) tablets



Please fax **COMPLETED** form to **1-844-257-6126** • For questions, call **1-800-887-8100** • 8 am-8 pm CT M-F

| DOB (MM/DD/YYYY):   |  |   | Gender: M   | ale  Female   | Unspecified   |  |  |
|---|--|---|---|---|---|--|--|
| Address:  |  |   |   | c.maio  | <u> </u>  |  |  |
| City:   |  |   |   | State:  | ZIP:  |  |  |
| Home Phone:   |  |   | Mobile:   | <u> </u>  |   |  |  |
| Email Address:  |  |   |   |   |   |  |  |
| ENROLL IN tevo  | Shared So  | lutions   |   |   |   |  |  |
|   | - •  |   | alth Information as set forth in the  | HIPAA Authorization o   | n page 2.   |  |  |
| TIENT OR PERSONAL REP   | RESENTATIVE SIG  | iNATURE:  |   |   | Date:   |  |  |
| If signed by someone oth  | er than the patie  | nt, complete the following in   | nformation:   |   | <del></del> -   |  |  |
| Name:   | ·  |   |   | Legal authority to sign on patient behalf:  |   |  |  |
| (including autodialed and<br>surveys, and to use my in<br>I understand that I may c   | I/or prerecorded<br>formation to dev<br>hoose to no long   | calls and/or messages), an elop future products, service er receive further communications. | d electronic messages for marketies, and programs.  | ng and promotional pound unsubscribe instruction  | ntact me by direct mail, email, telephone<br>urposes, to conduct market research or<br>ons on the communication. Opting in to |  |  |
| By checking this box,   | I am enrolling in  | the Teva <b>Shared Solutions</b>  |   | •   | g medication, coverage, or prescription   |  |  |
| 1011241105  |  | INCURANCE CARR. D   | UADUA OV DENESITO CARD (  |   |   |  |  |
|   |  |   | _   | _   | ust accompany form when faxe  |  |  |
| Medicare D N  |  | Pharmacy Insurance N  |   | Medical Insura  |   |  |  |
| Phone:  | Ph   | armaou ID#  |   |   |   |  |  |
|   |  | armacy ID#:   | Phone:  |   | iroup #:  |  |  |
| BIN #:  | PCN #:   | Group #:  | Policy Holder   | Name and DOB:   |   |  |  |
|   | PCN #:  R AUSTEDO  I Rx  se: ) x Week 1 ) x Week 2 D) x Week 3 D) x Week 4   | Group #:  | G24.01 Tardive Dyskinesia  r initial and/or current treat  CONTINUING  Titrate weekly by dose selected be   | (TD) G10 Hunting ment, filling in any & SAMPLED PATIE 6 mg/day from curre elow (select one): 8 mg BID) – Dose select I mg BID) 4 mg BID)              | ton's Chorea (HD)   |  |  |
| PRESCRIPTION FOR INITIAL TITRATION To reach 30 mg/day dos 12 mg/day (6 mg BID 18 mg/day (9 mg BID 24 mg/day (12 mg BII 30 mg/day (15 mg BI No Refills   | PCN #:  R AUSTEDO  I Rx se: ) x Week 1 ) x Week 2 D) x Week 3 D) x Week 4 al voucher   | Group #:  ICD-10 CODE  Check box below for  | Policy Holder  G24.01 Tardive Dyskinesia  r initial and/or current treat  CONTINUING  Titrate weekly by dose selected be  36 mg/day (18  42 mg/day (2  48 mg/day (2  Refills #: | Name and DOB:  (TD) G10 Hunting ment, filling in any  & SAMPLED PATIE 6 mg/day from currellow (select one): 8 mg BID) – Dose select mg BID) 4 mg BID) | rton's Chorea (HD)  |  |  |
| PRESCRIPTION FOR INITIAL TITRATION To reach 30 mg/day dos 12 mg/day (6 mg BID 18 mg/day (9 mg BID 24 mg/day (12 mg BII 30 mg/day (15 mg BI No Refills Apply 30-day free tria  | PCN #:  R AUSTEDO  I Rx  se: ) x Week 1 ) x Week 2 D) x Week 3 D) x Week 4  al voucher  m Tetrabenazine  cher for INITIAL R    | Group #:  ICD-10 CODE  Check box below for  *Sig:   | Policy Holder  G24.01 Tardive Dyskinesia  r initial and/or current treat  CONTINUING  Titrate weekly by dose selected be  36 mg/day (18  42 mg/day (2  48 mg/day (2  Refills #: | Name and DOB:  (TD) G10 Hunting ment, filling in any  & SAMPLED PATIE 6 mg/day from currellow (select one): 8 mg BID) – Dose select mg BID) 4 mg BID) | tion's Chorea (HD) Other ICD-10:  This blank fields.  This mg/day to reach the ction following initial 4-week titration       |  |  |
| PRESCRIPTION FOR INITIAL TITRATION To reach 30 mg/day dos 12 mg/day (6 mg BID 18 mg/day (9 mg BID 24 mg/day (12 mg BII 30 mg/day (15 mg BI No Refills Apply 30-day free trial Other Rx or Switch from Apply 30-day free trial vous Start at 50% of current TBZ  | PCN #:  R AUSTEDO  I RX se: ) x Week 1 ) x Week 2 D) x Week 3 D) x Week 4  I voucher  m Tetrabenazine cher for INITIAL R dose. | Group #:  ICD-10 CODE  Check box below for  *Sig:   | Policy Holder  G24.01 Tardive Dyskinesia  r initial and/or current treat  CONTINUING  Titrate weekly by dose selected be  36 mg/day (18  42 mg/day (2  48 mg/day (2  Refills #: | Name and DOB:  (TD) G10 Hunting ment, filling in any  & SAMPLED PATIE 6 mg/day from currellow (select one): 8 mg BID) – Dose select mg BID) 4 mg BID) | tion's Chorea (HD) Other ICD-10:  This blank fields.  This mg/day to reach the ction following initial 4-week titration       |  |  |
| PRESCRIPTION FOR INITIAL TITRATION To reach 30 mg/day dos 12 mg/day (6 mg BID 18 mg/day (9 mg BID 24 mg/day (12 mg BII 30 mg/day (15 mg BI No Refills Apply 30-day free trial Other Rx or Switch from Apply 30-day free trial vouc Start at 50% of current TBZ  | PCN #:  R AUSTEDO  Rx  Se: ) x Week 1 ) x Week 2 D) x Week 3 D) x Week 4  Al voucher  Tetrabenazine  Cher for INITIAL R  dose. | Group #:  ICD-10 CODE  Check box below for  *Sig:   | Policy Holder  G24.01 Tardive Dyskinesia  r initial and/or current treat  CONTINUING  Titrate weekly by dose selected be  36 mg/day (18  42 mg/day (2  48 mg/day (2  Refills #: | Name and DOB:  (TD) G10 Hunting ment, filling in any  & SAMPLED PATIE 6 mg/day from currellow (select one): 8 mg BID) – Dose select mg BID) 4 mg BID) | tion's Chorea (HD) Other ICD-10:  This blank fields.  This mg/day to reach the ction following initial 4-week titration       |  |  |
| PRESCRIPTION FOR INITIAL TITRATION To reach 30 mg/day dos 12 mg/day (6 mg BID 18 mg/day (9 mg BID 24 mg/day (12 mg BID 30 mg/day (15 mg BID No Refills Apply 30-day free trial Other Rx or Switch from Apply 30-day free trial vouc Start at 50% of current TBZ REFERRED PHARMA Name of Preferred Pha | PCN #:  R AUSTEDO  Rx  Se: ) x Week 1 ) x Week 2 D) x Week 3 D) x Week 4  Al voucher  Tetrabenazine  Cher for INITIAL R  dose. | Group #:  ICD-10 CODE  Check box below for  *Sig:   | Policy Holder  G24.01 Tardive Dyskinesia  r initial and/or current treat  CONTINUING  Titrate weekly by dose selected be  36 mg/day (18  42 mg/day (2  48 mg/day (2  Refills #: | Name and DOB:  (TD) G10 Hunting ment, filling in any  & SAMPLED PATIE 6 mg/day from currellow (select one): 8 mg BID) – Dose select mg BID) 4 mg BID) | tion's Chorea (HD) Other ICD-10:  This blank fields.  This mg/day to reach the ction following initial 4-week titration       |  |  |
| PRESCRIPTION FOR INITIAL TITRATION To reach 30 mg/day dos 12 mg/day (6 mg BID 18 mg/day (9 mg BID 24 mg/day (12 mg BII 30 mg/day (15 mg BI No Refills Apply 30-day free trial Other Rx or Switch from Apply 30-day free trial vouc Start at 50% of current TBZ  | PCN #:  R AUSTEDO  Rx  Se: ) x Week 1 ) x Week 2 D) x Week 3 D) x Week 4  Al voucher  Tetrabenazine  Cher for INITIAL R  dose. | Group #:  ICD-10 CODE  Check box below for  *Sig:   | Policy Holder  G24.01 Tardive Dyskinesia  r initial and/or current treat  CONTINUING  Titrate weekly by dose selected be  36 mg/day (18  42 mg/day (2  48 mg/day (2  Refills #: | Name and DOB:  (TD) G10 Hunting ment, filling in any  & SAMPLED PATIE 6 mg/day from currellow (select one): 8 mg BID) – Dose select mg BID) 4 mg BID) | tion's Chorea (HD) Other ICD-10:  This blank fields.  This mg/day to reach the ction following initial 4-week titration       |  |  |

## PRESCRIPTION AND SERVICE REQUEST FORM

AUSTEDO® (deutetrabenazine) tablets



Please fax COMPLETED form to 1-844-257-6126 • For questions, call 1-800-887-8100 • 8 am-8 pm CT M-F

| atient Name:  |   | DOB (MM/DD/YYYY):                    |                                  |  |  |  |
|---|---|--------------------------------------|----------------------------------|--|--|--|
|   |   |                                      |                                  |  |  |  |
| ACILITY INFORMATION   |   |                                      | □ VA                             |  |  |  |
| acility Name:   |   |                                      | Long-Term Care                   |  |  |  |
| Facility Phone:   |   |                                      | CMHC                             |  |  |  |
|   |   |                                      |                                  |  |  |  |
| RESCRIBER INFORMATION   |   |                                      |                                  |  |  |  |
| rescriber Name:   | Check if: MD  | Check if: ☐ MD ☐ NP ☐ PA ☐ DO NPI #: |                                  |  |  |  |
| ffice Address:  | City:   | State:                               | ZIP:                             |  |  |  |
| lurse/Office Contact:   | Phone:  | Fax:                                 |                                  |  |  |  |
|   |   |                                      |                                  |  |  |  |
| RESCRIBER SIGNATURE   |   |                                      |                                  |  |  |  |
| After discussing  | g the Program for AUSTEDO (including its agents, service prov<br>he Program. I authorize the release of medical and/or other pa   |                                      |                                  |  |  |  |
| Patient Services and Solutions, Inc., its affiliates and i  | its designated agents and service providers, including but no<br>tion related to this Program, and furnish any information in thi | t limited to dispensing pha          | rmacies of AUSTEDO, to use       |  |  |  |
|   | ated information by the Program, acting as my authorized age  |                                      |                                  |  |  |  |
|   | URE ONLY. Please attach all prescriptions on Official State Pre   |                                      |                                  |  |  |  |
|   | nic prescription requirements such as e-prescribing, state-s  | pecine prescription form, (          | or riard copy prescription, etc. |  |  |  |
| **STAMP SIGNATURE NOT PERMITTED – INK SIGNATU<br>The prescriber is to comply with his/her state-speci |   |                                      | Date:                            |  |  |  |
|   |   |                                      | oate:                            |  |  |  |
| The prescriber is to comply with his/her state-speci  | a Parmissihla   | <u> </u>                             | Date:                            |  |  |  |

## PATIENT AUTHORIZATION

I authorize my healthcare providers, pharmacies, and health plan(s) to disclose my personal health information on this form as well as information related to my medical condition, treatment, care management, prescriptions, and health insurance to Patient Services and Solutions, Inc. and its affiliates, contractors, and agents, including its third-party patient support program service provider (collectively "Teva") for the purposes described below. I understand that the purpose of this Authorization is to provide me with access to services related to my prescribed medication and/or medical condition ("Program"), including (i) enrollment in the Program; (ii) conducting benefits investigation and coordinating my insurance coverage, which may include allowing a Teva field-based representative to access my information and engage with my healthcare providers directly, if necessary; (iii) if needed, determining my eligibility for and coordinating financial assistance; (iv) coordinating prescription fulfillment and product replacement; (v) providing nursing support, including product administration training and education; (vi) facilitating quality and adverse event reporting activities; (vii) conducting data analytics, market research, and Program-related business activities; (viii) contacting me by direct mail or by electronic or telephonic means to the contact information on this form or to any future contact information provided by me or on my behalf in connection with carrying out the Program services, including adherence-related communications, reminders, and support, for which the third-party service provider may receive financial remuneration from the manufacturer of your medication. I understand that I may cancel this Authorization at any time, by writing to Teva, Attn: Authorizations, P.O. Box 5490, Louisville, KY 40255, but my cancellation will remain in effect until the Program ends. I understand that once my information is disclosed, it may be subject to redisclosure by the recipients and no longer protecte

Return completed form plus a front/back copy of the patient's insurance card and pharmacy benefit card to Teva Shared Solutions®

